WATCH l Remsdesivir not yet approved in Canada:The antiviral drug remdesivir is showing promise as a COVID-19 treatment in early U.S. clinical trials, though other research hasn’t seen as much success. Several scientists interviewed by Reuters felt the White House setting seemed inappropriate for the release of highly anticipated government-funded trial data on the Gilead therapy. In a statement on Wednesday, Gilead said the NIAID's much-anticipated trial had met its primary goal, but gave no details. Results from a third study in China suggesting remdesivir failed to help COVID-19 patients were released in the British medical journal the Lancet after review by a peer group of scientists. At the Oval Office news conference, Fauci compared the study findings to AZT, the first drug to show any benefit against HIV, decades ago.

Source: CBC News April 30, 2020 14:15 UTC